摘要 |
The present invention provides a compound of formula (I), wherein R1 and R2 are the same or different and are independently H, C1-C6 straight-chain or branched-chain saturated or unsaturated alkyl, aryl, R6CH2-, R6CO-, or R6SO2-, wherein R6 is H, C1-C6 straight-chain or branched-chain saturated or unsaturated alkyl, or aryl; R3 is H, C1-C6 straight-chain or branched-chain saturated alkyl, aryl, an oxime, or an oxime methyl ether; at least one aromatic ring position is optionally substituted with a substituent selected from the group consisting of halo, nitro, amino, hydroxyl, thio, acyl, C1-C6 alkyl, and cyano; and Z is a contiguous linker comprising a chain of 7-10 atoms (including heteroatoms) which atoms, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, which carbons are covalently bonded to either end of linker Z, integrally form a 12-15 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof. The present invention further provides a pharmaceutical composition, and a method of preventing or treating cancer, using at least one compound of the present invention, optionally in conjunction with an additional compound other than a compound of the present invention. |
申请人 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SE CRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
发明人 |
BOYD, MICHAEL R.;MCKEE, TAWNYA;CARDELLINA, JOHN H.;BEUTLER, JOHN A.;ERICKSON, KAREN;GALINIS, DEBORAH;PANNELL, LEWIS |